Keyphrases
ABCG2
19%
Advanced Breast Cancer
29%
Anthracyclines
15%
Bevacizumab
26%
Brain Metastases
29%
Breast Cancer
79%
Breast Cancer Patients
17%
Cancer Patients
15%
Capecitabine
15%
Carbohydrate Antigen 125 (CA125)
19%
Chemotherapy
27%
Colorectal Cancer
36%
Colorectal Cancer Patients
19%
Docetaxel
17%
Epirubicin
19%
Gemcitabine
21%
Hazard Ratio
15%
HER2-targeted Therapy
15%
Irinotecan
52%
Lapatinib
15%
Metastatic Breast Cancer
15%
Metastatic Colorectal Cancer (mCRC)
61%
Neoadjuvant Setting
21%
Oncology Outpatients
19%
Outpatient Clinic
15%
Overall Survival
26%
Oxaliplatin
28%
Phase II Study
15%
Phase II Trial
22%
Progression-free Survival
22%
PubMed
17%
Risk Factors
19%
Topoisomerase
19%
Trastuzumab
19%
Pharmacology, Toxicology and Pharmaceutical Science
ABCG2
19%
Anthracycline
19%
Bevacizumab
26%
Biological Marker
43%
Breast Cancer
100%
Capecitabine
21%
Chemotherapy
47%
Colorectal Carcinoma
44%
Cyclophosphamide
16%
Disease Free Survival
20%
Epidermal Growth Factor Receptor
29%
Epirubicin
19%
Fluorouracil
25%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
19%
Irinotecan
51%
Metastatic Breast Cancer
23%
Metastatic Colorectal Cancer
50%
Monoclonal Antibody
29%
Neoplasm
33%
Ovary Cancer
19%
Overall Survival
22%
Oxaliplatin
27%
Progression Free Survival
23%
Protein Tyrosine Kinase Inhibitor
19%
Rectum Cancer
21%
Solid Malignant Neoplasm
19%
Trastuzumab
38%
Medicine and Dentistry
Biological Marker
29%
Breast Cancer
58%
Breast Cancer Resistance Protein
19%
Colorectal Carcinoma
42%
Fluorouracil
16%
Irinotecan
29%
Malignant Neoplasm
23%
Metastatic Colorectal Cancer
21%
Oxaliplatin
22%
Progression Free Survival
18%
Rectum Cancer
20%
Systematic Review
38%
